TransCode Therapeutics adjourns 2026 annual meeting to July 20 pending Nasdaq initial listing review

TransCode Therapeutics adjourned its 2026 Annual Meeting to July 20, 2026 to await Nasdaq's review of its initial listing application.Key Highlights:Original SEC Filing: Transcode Therapeutics, Inc. [ RNAZ ] - 8-K - Jul. 02, 2026This is an AI-powered summary. It may contain inaccuracies. Consider v…

TransCode Therapeutics adjourned its 2026 Annual Meeting to July 20, 2026 to await Nasdaq's review of its initial listing application.

Key Highlights:

Adjourned reconvened Annual Meeting scheduled for July 20, 2026 at 9:30 a.m. ET for administrative reasons under Nasdaq rules.
Preliminary votes indicate all proposals received necessary support, but final action on Proposal 1 awaits Nasdaq approval of initial listing.
Record date for voting remains May 28, 2026; shareholders urged to vote by July 19, 2026 11:59 p.m. ET or before reconvened meeting.
Company believes it meets Nasdaq Capital Market listing criteria but cautions there are no assurances on timing or outcome of Nasdaq review.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.